Therapy proves effective in subgroup of COPD patients
An antibody treatment has been found to reduce the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant COPD...
List view / Grid view
An antibody treatment has been found to reduce the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant COPD...
A network of hospitals have systematically collected biopsies from metastatic cancer patients in order to create a global database...
A new biomedical tool has been developed using nanoparticles that deliver transient gene changes to targeted cells...
An experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumours...
Scientists have made progress in the development of products that improve mitochondrial function...
A new gene therapy that targets the heart and requires only one treatment session has been found safe for patients with coronary artery disease...
Phase 2 trial to explore targeted therapies for children with solid tumours that harbour specific genetic mutations which have progressed during or after standard therapy...
Researchers have found a pattern of genes which is characteristic of osteoarthritis and may be a step towards better treatments for this condition.
University of Warwick researchers are to improve the lives of India's millions of psychosis sufferers.
University of Warwick expertise is contributing to a world-first £1.5million study aiming to tackle one of the biggest public health threats we face - antibiotic resistance.
AMI has released the full version of HCC Coding as part of the EMscribe suite of tools in support of medical records processing and abstraction.
The ABPI has developed a new tool to help build research relationships between the pharmaceutical industry and UK academics.
Researchers have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease.
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.